What is the mechanism and effect of elastran in treating breast cancer?

Breast cancer is one of the most common female malignant tumors in the world. Among them, estrogen receptor-positive (ER+) breast cancer accounts for about 70% of all breast cancers. This type of breast cancer mainly relies on estrogen to promote the growth and proliferation of cancer cells, so endocrine therapy (by inhibiting the effects of estrogen) is the basis for the treatment of ER+ breast cancer. However, although endocrine therapy is effective in many patients initially, some patients develop drug resistance over time, leading to disease recurrence or metastasis. Elacestrant (Elacestrant), as a new type of selective estrogen receptor modulator (SERM), provides a new treatment option for these patients.

Elastran is a selective estrogen receptor modulator (SERM) that blocks the effects of estrogen in breast cancer cells by selectively modulating the function of estrogen receptors. It binds to and changes the estrogen receptor, changing the conformation of the estrogen receptor, thereby inhibiting the promotion effect of estrogen on tumor cells. The mechanism of elastran is different from traditional estrogen receptor antagonists (such as tamoxifen), because it not only competitively binds to estrogen receptors, but also induces conformational changes in the receptors, resulting in stronger inhibition of the biological activity of estrogen.

After elastran binds to estrogen receptors, it inhibits the stimulating effect of estrogen on cancer cells, thereby reducing the proliferation of tumor cells. Unlike other SERMs, elastran has greater selectivity and potency, which is particularly important in the treatment of endocrine-resistant breast cancer patients. For those patients who develop progressive disease due to resistance to endocrine therapy, elastran may exert therapeutic effects through its unique mechanism of action.

The therapeutic effect of elastran is mainly reflected in its ability to effectively inhibit the growth of estrogen-dependent breast cancer, especially for those patients who are resistant to traditional treatments. The proliferation of breast cancer cells is usually mediated by estrogen and its receptors, and elastran blocks this process, thereby inhibiting the growth of cancer cells. For patients with endocrine resistance, elastran, as a new treatment option, can not only delay disease progression, but also improve patients’ progression-free survival (PFS).

In clinical trials, elastran has been shown to be effective in patients with advanced or metastatic breast cancer, particularly those who are resistant or refractory to other endocrine treatment options. Compared with traditional estrogen receptor antagonists, elastran has shown unique advantages in controlling the disease and prolonging patient survival. By improving patients' symptoms and slowing tumor progression, elastran offers new therapeutic hope, especially for patients who have experienced failure of traditional treatments, making elastran a new option.

For patients with endocrine resistance, the therapeutic effect of elastran is particularly outstanding. Research shows that through its unique mechanism of action, elastran can significantly improve the efficacy of patients and prolong their survival. Its mode of action is not limited to anti-tumor growth, but also includes inhibiting the metastasis and invasion of tumor cells, thereby reducing the recurrence rate and the risk of metastasis.

Elastrast has been approved by the USFDA and has been clinically used in many countries and regions. It is mainly used to treat patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer, especially those who are resistant to endocrine therapy. Due to its superior pharmacological effects, elastran has been included in treatment guidelines and has become one of the first-line drugs in the treatment of breast cancer.

References:https://www.drugs.com/mtm/elacestrant.html